Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Gains from Investment Securities (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Gains from Investment Securities for 4 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities rose 287.81% to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.2 million, a 287.81% increase, with the full-year FY2025 number at $1.2 million, down 80.12% from a year prior.
  • Gains from Investment Securities was $1.2 million for Q3 2025 at Phathom Pharmaceuticals, down from $4.5 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $7.0 million in Q1 2025 to a low of -$1.2 million in Q3 2022.
  • A 4-year average of $2.6 million and a median of $1.6 million in 2023 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 334256.2% in 2023; the steepest drop was 752.14% in 2023.
  • Phathom Pharmaceuticals' Gains from Investment Securities stood at $1.7 million in 2022, then dropped by 9.98% to $1.6 million in 2023, then skyrocketed by 206.25% to $4.8 million in 2024, then plummeted by 74.69% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Gains from Investment Securities are $1.2 million (Q3 2025), $4.5 million (Q2 2025), and $7.0 million (Q1 2025).